Enhancing proteotoxic stress as an anticancer strategy

Oncotarget

Volumn 2, Issue 4, 2011, Pages 284-286

  Grant, Steven ^a  

^a Department of Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 INHIBITOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; PUROMYCIN; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL; CANCER RECURRENCE; CELL PROTECTION; CELL STIMULATION; CELL STRESS; CELL TRANSFORMATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; HUMAN; IN VITRO STUDY; MANTLE CELL LYMPHOMA; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TREATMENT PLANNING; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; METHODOLOGY; NEOPLASM; NOTE; PHYSIOLOGY; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; UNFOLDED PROTEIN RESPONSE; UP-REGULATION;

EID: 80053299079     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.268     Document Type: Article

References (19)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
2. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136(5):823-837.
3. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992;359(6395):554-556.
4. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007.
5. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8(7):519-529.
6. Lin JH, Li H, Yasumura D et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 2007;318(5852):944-949.
7. Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 2004;10(2):47-51.
8. Guo F, Rocha K, Bali P et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylaminodemethoxy geldanamycin. Cancer Res 2005;65(22):10536-10544.
9. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107(12):4907-4916.
10. Mimnaugh EG, Xu W, Vos M et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004;3(5):551-566.
11. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115(6):727-738.
12. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003;102(10):3765-3774.
13. Rao R, Nalluri S, Fiskus W et al. Role of C/EBP homologous protein (CHOP) in Panobinostat-mediated potentiation of Bortezomib-induced lethal ER stress in Mantle Cell Lymphoma cells. Clin Cancer Res 2010.
14. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2011;2(3):209-221.
15. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007;21(24):3214-3231.
16. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432(7015):316-323.
17. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318(5848):287-290.
18. Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 2010;115(11):2127-2135.
19. Rahmani M, Davis EM, Crabtree TR et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 2007;27(15):5499-5513.